Skip to content
Edgewise Therapeutics Logo

Edgewise Therapeutics: Positive Topline Results from EDG-5506 Phase 1 Study

November 1, 2021

Defeat Duchenne Canada is pleased to share news from Edgewise Therapeutics regarding positive top-line results from their EDG-5506, a small molecule myosin inhibitor, Phase 1 Study in Duchenne and Becker muscular dystrophy. Although still early stages, we are very encouraged by these results and glad to see the emphasis on Becker muscular dystrophy, a large unmet need in our community. We hope to see more trial opportunities coming to Canada and remain committed to informing our community when they do.

Click the button below to read the full press release.

“We are excited by the potential that EDG-5506 may serve as an oral treatment to decrease muscle damage, the root cause of DMD and BMD, and we eagerly look forward to better understanding its full potential in future clinical studies.”

Dr. Joanne Donovan, M.D., Ph.D., Chief Medical Officer for Edgewise

Dr. Donovan will be presenting these results and the latest research to the Canadian Duchenne and Becker community at our upcoming virtual Defeat Duchenne Family Forum on November 5-7, 2021. Click here to learn more and register for the forum: